Innate Pharma S.A.
IPH.PA · PAR
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | €13 | €52 | €50 | €12 |
| % Growth | -75.7% | 4.6% | 309.8% | – |
| Cost of Goods Sold | €52 | €56 | €52 | €47 |
| Gross Profit | -€32 | €6 | €6 | -€35 |
| % Margin | -252.4% | 10.8% | 12.1% | -288.1% |
| R&D Expenses | €52 | €56 | €52 | €47 |
| G&A Expenses | €20 | €12 | €14 | €16 |
| SG&A Expenses | €18 | €12 | €22 | €26 |
| Sales & Mktg Exp. | €0 | €0 | €8 | €10 |
| Other Operating Expenses | -€50 | -€49 | -€11 | -€47 |
| Operating Expenses | €20 | €18 | €63 | €26 |
| Operating Income | -€52 | -€13 | -€25 | -€48 |
| % Margin | -408.6% | -24.4% | -49.6% | -394.9% |
| Other Income/Exp. Net | €2 | €5 | -€1 | €2 |
| Pre-Tax Income | -€57 | -€8 | -€58 | -€45 |
| Tax Expense | -€7 | €0 | €0 | €0 |
| Net Income | -€49 | -€8 | -€58 | -€53 |
| % Margin | -391.9% | -14.6% | -117.1% | -436% |
| EPS | -0.61 | -0.094 | -0.73 | -0.74 |
| % Growth | -548.2% | 87.1% | 1.4% | – |
| EPS Diluted | -0.61 | -0.094 | -0.73 | -0.66 |
| Weighted Avg Shares Out | 61 | 61 | 61 | 61 |
| Weighted Avg Shares Out Dil | 81 | 80 | 80 | 80 |
| Supplemental Information | – | – | – | – |
| Interest Income | €6 | €3 | €1 | €0 |
| Interest Expense | €4 | €1 | €0 | €0 |
| Depreciation & Amortization | €2 | €5 | €4 | €5 |
| EBITDA | -€51 | -€2 | -€61 | -€43 |
| % Margin | -404% | -3.5% | -123.5% | -356.9% |